iSiP develops an "AI drug discovery 3.0" platform that fuses AI/machine learning, physics-based simulation, and high-performance computing (HPC) to design compounds for targets lacking extensive prior data. The company emphasizes an HPC approach that does not require dedicated large-scale supercomputers, enabling workflows that can run on personal-level hardware. iSiP reports markedly lower cost and time to hit compounds (costs reduced to under one-tenth and timelines to under one-half) versus prior methods, and claims successful hit acquisition for difficult targets without labeled training data. A cited example is PAC1, where the company obtained over 40 novel-scaffold antagonists with a 93% hit rate and plans to advance these into lead optimization. iSiP says it pursues a market-in strategy—prioritizing targets with clear demand from large pharmaceutical partners—and maintains collaborations with academic groups including the University of Tokyo and Kyoto University. The company was founded in 2022 and is headquartered in Bunkyo-ku, Tokyo. It recently completed a financing to support its proprietary platform and ongoing discovery programs.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2023